Article -> Article Details
Title | Heart Tumor Market Competitive Analysis to 2023 |
---|---|
Category | Fitness Health --> Addictions |
Meta Keywords | Heart Tumor Market |
Owner | vinit |
Description | |
Market Highlights The prevalence of primary cardiac tumors is 0.001-0.03%.
Secondary tumors are 20-40 found to be more common than primary tumors because
15% of patients with any form of cancer exhibit metastases to the heart.
According to the WHO, cancer is the leading cause of death worldwide,
accounting for 8.8 million deaths in 2015. Globally, lung cancer accounted for
1.69 million deaths and subsequently, breast cancer caused 571,000 deaths in
2015. The global heart
tumor market is expected to grow at a CAGR of approximately
7.1% during the forecast period 2017-2023. The cardiac tumor is an abnormal growth of tissues in the
heart or heart valves. Cardiac tumors are rare and can be cancerous or
noncancerous. Tumors that originate in the heart and are bound to stay there
are called primary tumors. On the contrary, tumors that grow in some other part
of the body and spreads to the heart i.e. metastasize are called secondary
tumors. Cardiac neoplasm is a rare pathological condition associated
with non-specific signs and symptoms and must be considered while treating
conditions like cardiac arrhythmia, ischemic syndromes, and Hiss-Purkinje
conduction system dysfunction. Sometimes drugs can be injected into the pericardial
area of the heart to slow the tumor growth. During the surgery, the surgeon
removes the tumor and the tissue around it to reduce the risk of tumor
recurrence. Increasing incidence of cancer metastasis and high technological
advancement with the rising adoption promotes the growth of the heart tumor
market. Regional Analysis The global heart tumor consists of regions namely the
America, Europe, Asia Pacific, and the Middle East & Africa. North America dominates the global heart tumor market. The
Asia Pacific region is growing at a higher rate than any other region globally.
The demand for diagnostic outpatient surgeries is increasing, which in turn,
increasing the growth of the Asia Pacific heart tumor market. In India, increasing number of hospitals and healthcare
services, availability of low cost of raw material, and better access to labor
drive the growth of this market. Australia and the Republic of Korea are
experiencing slow growth in the imaging devices and heart tumors market. Segmentation The heart tumor market is segmented on the basis of type,
diagnosis, treatment. On the basis of the type, the market is segmented into the
primary tumor and secondary tumor. The primary tumors are divided into benign and
malignant. The benign tumor is further categorized into myxoma, papillary heart
tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are
divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell
tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumors are
categorized into metastatic and by contiguity. The metastatic secondary tumors
are divided into hematogenic and lymphatic and the contiguity is
sub-categorized into mediastinal tumors, lung tumors and oesophageal, or cardia
tumor. On the basis of diagnosis, the market is classified into
Echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging
(MRI), Radionuclide imaging, Positron Emission Tomography (PET) Scan,
myocardial biopsy, cardiac catheterization, electrophysiology test. On the basis of the treatment, the market is classified as
surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further
categorized into open heart surgery, minimally invasive surgery, and heart
transplant surgery Key Players Some of key the players in the global heart tumor market are
Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers,
Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation,
CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging,
HeartSciences, 3mensio Medical Imaging, and eMedica, S.L. |